Table 3.

Prevalence of MDR-TB and rifampicin resistance from 1995 to 2016

Prevalences	1995 [8]	2006 [9]	2016
	New cases (n = 320)	New cases (n = 320)	New cases (n = 995)	Previously treated (n = 100)
Rifampicine resistance	Not applicable	Not applicable	46 (4.6%) (95% CI: 2.4–6.8%)	22 (22%) (95% CI: 13.7–30.3%)
MDR-TB	17 (5.3%)	8 (2.5%)	mE*: 3.3% (95% CI: 1.9–4.8%)	mE*: 19.2% (95% CI: 10.8–27.6%)
	(95% CI: 3.1–8.4%)	(95% CI: 1.1–4.9%),	ME: 4.5% (95% CI: 2.4–6.7%)	ME: 21.2% (95% CI: 13.0–29.4%)

CI: confidence interval; mE : minimum estimation of MDR-TB prevalence; ME: maximum estimation MDR-TB prevalence.